Valsartan (Diovan): A Cardiologist's Guide to the ARB, Dosing, and Heart Failure Use

Valsartan (Diovan) is the angiotensin receptor blocker (ARB) most patients in my Encinitas practice end up on at some point, either as monotherapy for hypertension or as the ARB component of sacubitril-valsartan (Entresto) for heart failure. It has one of the deepest trial evidence bases in the class and is well tolerated. This guide walks through how it works, the indications, dosing, monitoring, and where it sits in modern cardiovascular care.

What Is Valsartan?

Valsartan is an angiotensin receptor blocker (ARB) that selectively blocks the AT1 receptor for angiotensin II, lowering blood pressure, reducing the workload on the heart, and protecting the kidneys. It is one of the most studied ARBs and the most clinically versatile across hypertension, heart failure, and post-MI care.

The renin-angiotensin-aldosterone system (RAAS) is an ancient hormone circuit that regulates blood pressure and salt/water balance. Angiotensin II is the workhorse hormone: it constricts blood vessels, signals the kidneys to retain sodium and water, drives thirst, and stimulates cardiac and vascular remodeling. Valsartan blocks the AT1 receptor where angiotensin II would otherwise act, shutting down the constrictive, pro-fibrotic, and salt-retaining effects. The unblocked AT2 receptor (which has more protective effects) remains active.

Valsartan’s pharmacokinetic profile is well-suited to once-daily dosing in hypertension. Peak effect comes at 4 to 6 hours and the half-life is about 6 hours, but the duration of biologic action is 24 hours. In heart failure, it is dosed twice daily because the lower bioavailable doses used (40 to 160 mg twice daily) have a shorter effective duration.

What Is Valsartan Used For?

Three main indications: hypertension, heart failure with reduced ejection fraction (as sacubitril-valsartan, the modern standard), and post-myocardial infarction in patients who do not tolerate ACE inhibitors. Combination products bundle valsartan with hydrochlorothiazide (Diovan HCT), amlodipine (Exforge), or sacubitril (Entresto).

Valsartan Indications and Typical Dosing

Hypertension is the highest-volume indication. The 2017 ACC/AHA hypertension guideline target is below 130/80 mmHg in most adults. Valsartan alone reduces systolic blood pressure by about 10 to 15 mmHg in mild to moderate hypertension and is comparable to other ARBs and ACE inhibitors on average. When monotherapy is insufficient, the standard add-ons per the ACCOMPLISH trial framework are a calcium channel blocker (amlodipine, available as Exforge) or a thiazide diuretic (chlorthalidone, hydrochlorothiazide, or indapamide, available as Diovan HCT).

Heart failure with reduced ejection fraction (HFrEF) has shifted from valsartan monotherapy to sacubitril-valsartan as the foundational ARB-based therapy. The PARADIGM-HF trial showed that sacubitril-valsartan reduced cardiovascular death and heart failure hospitalization by 20% compared to enalapril. Most patients who would have received valsartan or an ACE inhibitor for HFrEF a decade ago are now started on sacubitril-valsartan instead. Plain valsartan remains an option when sacubitril cannot be used (hypotension, history of angioedema with sacubitril, cost).

Post-myocardial infarction with left ventricular dysfunction or heart failure is a defined indication backed by the VALIANT trial, which showed valsartan non-inferior to captopril (the gold-standard ACE inhibitor in this setting). For patients who develop ACE inhibitor cough or angioedema after MI, valsartan is the cleanest substitution.

How Does Valsartan Compare to Other ARBs?

Among the seven ARBs (losartan, valsartan, candesartan, irbesartan, telmisartan, olmesartan, azilsartan), valsartan has the deepest evidence base in heart failure and post-MI care. Losartan is the cheapest. Irbesartan has the strongest diabetic nephropathy data (IDNT, IRMA-2). Candesartan has the strongest HFpEF data (CHARM-Preserved). Telmisartan has the longest half-life.

The within-class differences are smaller than the differences between ARBs and other antihypertensive classes. For straight hypertension, any ARB will work and the choice usually comes down to cost (losartan is cheapest) and combination product availability. For specific indications, the trial evidence guides selection:

• Heart failure with reduced ejection fraction: valsartan (Val-HeFT, PARADIGM-HF as sacubitril-valsartan) or candesartan (CHARM-Alternative)
• Heart failure with preserved ejection fraction: candesartan (CHARM-Preserved, modest benefit)
• Post-myocardial infarction: valsartan (VALIANT)
• Diabetic nephropathy: irbesartan (IDNT, IRMA-2), losartan (RENAAL)
• LVH regression in hypertension: losartan (LIFE)
• Cost-sensitive prescribing: losartan or valsartan generic

I default to valsartan for patients who may eventually need sacubitril-valsartan, because the transition is then a simple substitution rather than a switch between drug classes.

How Is Valsartan Dosed?

For hypertension: start at 80 or 160 mg once daily, titrate up to 320 mg as needed. For heart failure: start at 20 to 40 mg twice daily, titrate to 160 mg twice daily over 2 to 4 weeks. For sacubitril-valsartan: start at 24/26 to 49/51 mg twice daily, titrate to 97/103 mg twice daily over 2 to 4 weeks.

The hypertension dosing is the simplest. Most patients start at 80 mg or 160 mg once daily, and the dose is titrated up to 320 mg if blood pressure remains above target. Combination products (Diovan HCT, Exforge) layer in a second mechanism when monotherapy is insufficient.

Heart failure dosing is more cautious because hypotension can be limiting. The Val-HeFT protocol titrated from 40 mg BID up to 160 mg BID over several weeks. Most patients tolerate the upward titration if blood pressure and kidney function are monitored.

Sacubitril-valsartan has its own titration. Patients who are already on a maximally tolerated ACE inhibitor or ARB can typically start at the 49/51 mg BID dose (the middle of the three available strengths) and titrate up to the target 97/103 mg BID. Patients who are ACE/ARB naive or who have hypotension start at 24/26 mg BID. A 36-hour washout is required between an ACE inhibitor and sacubitril-valsartan to avoid the angioedema risk that comes from combining ACE inhibition with neprilysin inhibition.

For post-MI dosing per VALIANT, start at 20 mg BID and titrate to 160 mg BID over 1 to 3 months as tolerated, depending on blood pressure and kidney function.

Valsartan is dosed independently of meals and at any time of day. Most patients prefer the morning for once-daily dosing or 12 hours apart for twice-daily dosing. Missing a dose: take it as soon as remembered if it is the same day; skip and resume schedule if the next dose is due soon. Never double up.

What Should Be Monitored on Valsartan?

Check serum creatinine and potassium within 1 to 2 weeks of starting or increasing the dose, and periodically thereafter. A creatinine rise up to 30% is expected and acceptable. Potassium rises modestly. Larger creatinine jumps warrant investigation for dehydration, renal artery stenosis, NSAID co-administration, or contrast exposure.

The creatinine rise on an ARB has a defined mechanism: AT1 blockade relaxes the efferent arteriole in the glomerulus, which lowers intraglomerular filtration pressure and produces a small but expected rise in serum creatinine. This is a sign the drug is working at the kidney level, not a sign of harm. A 30% rise is acceptable. A larger jump (or progressive climb over weeks) warrants workup for:

• Bilateral renal artery stenosis (or stenosis in a single functioning kidney): consider renal artery imaging
• Volume depletion (over-diuresis, GI loss, poor intake): assess and replete
• NSAID co-administration: NSAIDs blunt renal autoregulation and can precipitate AKI when combined with ARBs
• Recent IV contrast (cardiac cath, CT angiography)

Potassium monitoring matters because suppression of aldosterone reduces potassium excretion. The rise is small in patients with normal kidney function and no potassium-sparing co-medications, but can reach dangerous levels in CKD, with spironolactone or eplerenone, with potassium supplements, or with the trimethoprim component of TMP-SMX.

For blood pressure itself, home blood pressure averages over 5 to 7 days are more reliable than a single office reading for titration decisions. Home blood pressure monitoring with a validated cuff is the standard.

When Should Valsartan Be Avoided?

Avoid in pregnancy (severe fetal harm including renal failure and oligohydramnios), bilateral renal artery stenosis (risk of sudden AKI), prior ACE inhibitor angioedema (about 3.5% cross-reactivity), severe pre-existing hyperkalemia (potassium > 5.5 mEq/L), and concurrent aliskiren in diabetic patients (ALTITUDE trial showed harm).

Pregnancy is an absolute contraindication. Valsartan and the entire ARB class cause severe fetal harm in the second and third trimesters, including renal failure, oligohydramnios, lung hypoplasia, and skull hypoplasia. First-trimester exposure carries a smaller but real signal. Women of reproductive age on valsartan need reliable contraception. Any pregnancy or planned pregnancy requires immediate switch to a pregnancy-safe agent (methyldopa, labetalol, nifedipine) and maternal-fetal medicine consultation.

Bilateral renal artery stenosis (or stenosis in a single functioning kidney) is the most dangerous renovascular contraindication. The kidneys depend on angiotensin II’s vasoconstrictive effect on the efferent arteriole to maintain adequate filtration pressure when renal blood flow is restricted. Blocking it can produce sudden acute kidney injury. Screen for this in patients with severe difficult-to-control hypertension or in those whose creatinine rises dramatically after starting an ARB.

Prior ACE inhibitor angioedema is a relative contraindication. The cross-reactivity rate to ARBs is about 3.5%. For mild ACE-inhibitor angioedema and a strong indication for RAAS blockade, valsartan can be tried cautiously with patient counseling. For severe airway angioedema on an ACE inhibitor, a different class entirely is safer.

Severe baseline hyperkalemia (potassium > 5.5 mEq/L) should be corrected first. Patiromer or sodium zirconium cyclosilicate are options for chronic management of hyperkalemia in patients who need ARB therapy for HFrEF or kidney protection but cannot tolerate the potassium rise alone.

Concurrent aliskiren in diabetic patients is contraindicated per the ALTITUDE trial, which showed increased adverse events when these were combined.

What About the 2018-2019 Valsartan Recalls?

The 2018-2019 valsartan, losartan, and irbesartan recalls were caused by an NDMA (N-nitrosodimethylamine) contaminant in products from specific manufacturers (Zhejiang Huahai, Hetero Labs, others). The FDA worked with manufacturers to clean up the impurities. Generic valsartan sold in US pharmacies today has been re-approved and is safe.

In July 2018, the FDA announced a recall of certain generic valsartan products after detecting NDMA, a probable human carcinogen, in the active pharmaceutical ingredient (API) made by some Chinese and Indian manufacturers. Subsequent recalls extended to other ARBs and other manufacturers through 2019. The FDA tightened the API testing requirements and worked with manufacturers to identify and eliminate the impurity source (related to a synthesis route using certain solvents).

Generic valsartan sold in US pharmacies today comes from manufacturers whose products have been re-approved by the FDA after demonstrating clean NDMA testing. The risk to patients who took the recalled product has been studied, and large cohort analyses have not identified a measurable cancer signal at the individual patient level, although the precautionary recall was clearly appropriate.

If a patient is anxious about a specific lot of valsartan, the FDA recall list and the pharmacist can confirm whether the product is from an affected lot. The risk-benefit calculation for current generic valsartan strongly favors continued use for the patients who need it.

What Is Sacubitril-Valsartan and How Does It Differ from Plain Valsartan?

Sacubitril-valsartan (Entresto) combines valsartan with sacubitril, a neprilysin inhibitor that prevents the breakdown of endogenous natriuretic peptides. The PARADIGM-HF trial showed it reduced cardiovascular death and HF hospitalization by 20% compared to enalapril. It is now the foundational ARB-based therapy for HFrEF, replacing ACE inhibitors and plain ARBs in most cases.

Sacubitril is the first-in-class neprilysin inhibitor. Neprilysin is an enzyme that breaks down natriuretic peptides (ANP, BNP, CNP) and other vasoactive peptides. Inhibiting neprilysin preserves these natriuretic peptides, which produce vasodilation, natriuresis, and antifibrotic effects, all complementary to ARB-mediated RAAS blockade. The combination is more powerful than either component alone.

A few practical points about sacubitril-valsartan:

• Do not combine with an ACE inhibitor. A 36-hour washout is required between an ACE inhibitor and sacubitril-valsartan. The combination produces unacceptable angioedema risk because both neprilysin inhibition and ACE inhibition raise bradykinin levels.
• BNP becomes uninterpretable. Because BNP is a neprilysin substrate, BNP levels rise paradoxically on sacubitril-valsartan and no longer reflect heart failure severity. Use NT-proBNP (not metabolized by neprilysin) instead for HF monitoring on this drug.
• Cost was historically a barrier. A generic version is now available, which has substantially lowered the out-of-pocket cost for many patients.

For HFrEF patients who tolerate valsartan, the transition to sacubitril-valsartan is usually straightforward and produces additional benefit. For HFpEF patients, the trial evidence (PARAGON-HF) was less clear-cut, and sacubitril-valsartan has a more nuanced role.

Valsartan: The Bottom Line

Valsartan is one of the most clinically versatile ARBs, with deep trial evidence across hypertension, heart failure, and post-MI care. It is the ARB component of sacubitril-valsartan, the modern foundation for HFrEF therapy. It is well tolerated, available as inexpensive generics, and is appropriate for first-line use in most patients who need RAAS blockade.

If your cardiologist has prescribed valsartan, you are on one of the most evidence-based cardiovascular drugs available. Take it consistently, attend the follow-up lab checks (creatinine and potassium within 1 to 2 weeks of any dose change), and call about any new symptoms that might warrant a class switch (cough, lightheadedness, muscle weakness suggesting hyperkalemia, or pregnancy).

Frequently Asked Questions About Valsartan

What is valsartan used for?

Three main FDA-approved uses: hypertension (high blood pressure), heart failure with reduced ejection fraction (especially as sacubitril-valsartan / Entresto), and post-myocardial infarction in patients with reduced LV function who cannot tolerate ACE inhibitors. It is also used for diabetic and non-diabetic kidney protection.

Is valsartan the same as Diovan?

Yes. Diovan is the original brand name for valsartan. Generic valsartan is now widely available and is the same active ingredient at the same dose with the same effect.

What is the difference between valsartan and sacubitril-valsartan (Entresto)?

Sacubitril-valsartan combines valsartan with sacubitril, a neprilysin inhibitor that preserves natriuretic peptides. The combination is more powerful than valsartan alone in heart failure and is now the foundational ARB-based therapy for HFrEF based on the PARADIGM-HF trial.

Is generic valsartan safe after the 2018-2019 recalls?

Yes. The recalls were caused by an NDMA contaminant in API from specific manufacturers. The FDA worked with manufacturers to clean up the impurities. Generic valsartan in US pharmacies today has been re-approved and is safe.

Can I take valsartan during pregnancy?

No. Valsartan and the entire ARB class cause severe fetal harm including renal failure, oligohydramnios, lung hypoplasia, and skull hypoplasia. Women of reproductive age on valsartan need reliable contraception. Any planned or confirmed pregnancy requires immediate switch to a pregnancy-safe agent.

What blood tests do I need on valsartan?

Serum creatinine and potassium within 1 to 2 weeks of starting or increasing the dose, then periodically thereafter. A creatinine rise up to 30% is expected and acceptable. Larger rises warrant investigation.

Can I take valsartan with an SGLT2 inhibitor and a GLP-1?

Yes. For many patients with diabetes, kidney disease, or heart failure, that combination is exactly the right plan. Valsartan, an SGLT2 inhibitor, and a GLP-1 receptor agonist each protect the heart and kidneys through a different pathway and the benefits stack.

Why did my doctor switch me from lisinopril to valsartan?

Most commonly because of a dry cough caused by lisinopril (an ACE inhibitor). ACE inhibitors cause cough in 4 to 20% of patients through bradykinin accumulation in the airways. Valsartan and other ARBs do not affect bradykinin and so rarely cause cough. The cardiovascular benefit is comparable per the ONTARGET trial.

References

1. Cohn JN, Tognoni G. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure (Val-HeFT). New England Journal of Medicine. 2001;345(23):1667-1675.

2. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (VALIANT). New England Journal of Medicine. 2003;349(20):1893-1906.

3. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in Hypertensive Patients at High Cardiovascular Risk Treated with Regimens Based on Valsartan or Amlodipine (VALUE). Lancet. 2004;363(9426):2022-2031.

4. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF). New England Journal of Medicine. 2014;371(11):993-1004.

5. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction (PARAGON-HF). New England Journal of Medicine. 2019;381(17):1609-1620.

6. ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine. 2008;358(15):1547-1559.

7. Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes (ALTITUDE). New England Journal of Medicine. 2012;367(23):2204-2213.

8. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115.

9. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients (ACCOMPLISH). New England Journal of Medicine. 2008;359(23):2417-2428.

10. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2022;79(17):e263-e421.